Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Receivables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Receivables for 4 consecutive years, with $476133.0 as the latest value for Q3 2025.

  • On a quarterly basis, Receivables fell 65.41% to $476133.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $476133.0, a 65.41% decrease, with the full-year FY2024 number at $1.2 million, up 38.74% from a year prior.
  • Receivables was $476133.0 for Q3 2025 at bioAffinity Technologies, up from $441385.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.7 million in Q2 2024 to a low of $9930.0 in Q3 2022.
  • A 4-year average of $724874.0 and a median of $841227.0 in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 11109.91% in 2023, then plummeted 74.26% in 2025.
  • bioAffinity Technologies' Receivables stood at $20978.0 in 2022, then skyrocketed by 3910.04% to $841227.0 in 2023, then surged by 38.74% to $1.2 million in 2024, then plummeted by 59.2% to $476133.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Receivables are $476133.0 (Q3 2025), $441385.0 (Q2 2025), and $981125.0 (Q1 2025).